Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 2/20 | 0.81 |
| ▸ | RAB9A | P51151 | 9/20 | 0.79 |
| ▸ | NPC1 | O15118 | 8/20 | 0.79 |
| ▸ | MEN1 | O00255 | 6/20 | 0.79 |
| ▸ | KMT2A | Q03164 | 6/20 | 0.79 |
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.62 |
| ▸ | HPGD | P15428 | 3/20 | 0.62 |
| ▸ | POLB | P06746 | 3/20 | 0.62 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.61 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.60 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.60 |
| ▸ | KCNK3 | O14649 | 1/20 | 0.58 |
| ▸ | KCNK9 | Q9NPC2 | 1/20 | 0.58 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.56 |
| ▸ | LMNA | P02545 | 1/20 | 0.56 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.56 |
| ▸ | HTT | P42858 | 1/20 | 0.56 |
| ▸ | TSHR | P16473 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29397956 | 0.90 | MAPT (1.00) | MAPTRAB9ANPC1MEN1KMT2A | |
| SCHEMBL259605 | 0.90 | MAPT (1.00) | MAPTRAB9ANPC1MEN1KMT2A | |
| SCHEMBL274082 | 0.82 | MAPT (0.70) | MAPTRAB9ANPC1MEN1KMT2A | |
| SCHEMBL16714080 | 0.81 | KMT2A (0.74) | MAPTRAB9ANPC1MEN1KMT2A | |
| SCHEMBL4738827 | 0.81 | MEN1 (0.67) | MAPTRAB9ANPC1MEN1KMT2A | |
| SCHEMBL4743668 | 0.81 | MEN1 (0.70) | MAPTRAB9ANPC1MEN1KMT2A | |
| SCHEMBL11246385 | 0.80 | MEN1 (1.00) | MAPTRAB9ANPC1MEN1KMT2A | |
| SCHEMBL14075227 | 0.78 | MEN1 (0.78) | RAB9ANPC1MEN1KMT2ASMN1; SMN2 | |
| SCHEMBL13137734 | 0.78 | MEN1 (0.62) | MAPTRAB9ANPC1MEN1KMT2A | |
| SCHEMBL12112027 | 0.77 | NPC1 (0.58) | MAPTRAB9ANPC1MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8067586-B2 | Fused heteroaryl derivatives | ASTELLAS PHARMA INC. (JP) | 2011-11-29 | — | — | US | disclosed |
| EP-1277738-B1 | CONDENSED HETEROARYL DERIVATIVES | ASTELLAS PHARMA INC (JP) | 2011-03-30 | — | — | EP | disclosed |
| US-20100137584-A1 | FUSED HETEROARYL DERIVATIVES | HAYAKAWA MASAHIKO | 2010-06-03 | — | — | US | disclosed |
| US-20100137585-A1 | FUSED HETEROARYL DERIVATIVES | HAYAKAWA MASAHIKO | 2010-06-03 | — | — | US | disclosed |
| WO-2008092861-A1 | BICYCLIC DERIVATIVES AS EP4 AGONISTS | JANSSEN PHARMACEUTICA N.V. (BE) | 2008-08-07 | — | — | WO | disclosed |
| US-20070037805-A1 | Fused heteroaryl derivatives | HAYAKAWA MASAHIKO | 2007-02-15 | — | — | US | disclosed |
| US-7173029-B2 | Fused heteroaryl derivatives | ASTELLAS PHARMA INC. (JP) | 2007-02-06 | — | — | US | disclosed |
| US-7037915-B2 | Fused heteroaryl derivatives | ASTELLAS PHARMA INC. (JP) | 2006-05-02 | — | — | US | disclosed |
| US-20060058321-A1 | Fused heterolaryl derivatives | HAYAKAWA MASAHIKO | 2006-03-16 | — | — | US | disclosed |
| US-20050014771-A1 | Fused heteroaryl derivatives | ASTELLAS PHARMA INC. (JP) | 2005-01-20 | — | — | US | disclosed |
| US-6838457-B2 | Fused heteroaryl derivatives | YAMANOUCHI PHARMACEUTICAL CO., LTD. (JP) | 2005-01-04 | — | — | US | disclosed |
| US-6770641-B2 | Fused heteroaryl derivatives | YAMANOUCHI PHARMACEUTICAL CO., LTD. (JP) | 2004-08-03 | — | — | US | disclosed |
| US-20040009978-A1 | Fused heteroaryl derivatives | ASTELLAS PHARMA INC. (JP) | 2004-01-15 | — | — | US | disclosed |
| US-20030236271-A1 | Fused heteroaryl derivatives | ASTELLAS PHARMA INC. (JP) | 2003-12-25 | — | — | US | disclosed |
| US-6608056-B1 | Phosphatidylinositol 3-kinase inhibitors and carcinostatic agents | YAMANOUCHI PHARMACEUTICAL CO., LTD (JP) | 2003-08-19 | — | — | US | disclosed |
| US-6608053-B2 | Phosphatidylinositol 3-kinase (PI3K) inhibitors/anticancer agents such as N-(2-(3-benzenesulfonylaminophenyl)-4-morphoniloquinazolin-6-yl)acetamide | YAMANOUCHI PHARMACEUTICAL CO., LTD. (JP) | 2003-08-19 | — | — | US | disclosed |
| EP-1277738-A1 | CONDENSED HETEROARYL DERIVATIVES | YAMANOUCHI PHARMACEUTICAL CO. LTD. (JP) | 2003-01-22 | — | — | EP | disclosed |
| US-20020151544-A1 | Fused heteroaryl derivatives | ASTELLAS PHARMA INC. (JP) | 2002-10-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030236271-A1 | Fused heteroaryl derivatives | PIK3CD, PIK3R3, PIK3C2A | MAPT 3923/4885RAB9A 613/4885NPC1 1963/4885 |
| US-20040009978-A1 | Fused heteroaryl derivatives | PIK3CD, PIK3R3, PIK3C2A | MAPT 3923/4885RAB9A 613/4885NPC1 1963/4885 |
| US-20100137584-A1 | FUSED HETEROARYL DERIVATIVES | PIK3CD, PIK3R3, PIK3C2A | MAPT 3923/4885RAB9A 613/4885NPC1 1963/4885 |
| US-20060058321-A1 | Fused heterolaryl derivatives | PIK3CD, PIK3C2A, PIK3R1 | MAPT 4063/4885RAB9A 789/4885NPC1 2418/4885 |
| US-20070037805-A1 | Fused heteroaryl derivatives | PIK3CD, PIK3R3, PIK3C2A | MAPT 3923/4885RAB9A 613/4885NPC1 1963/4885 |
| US-20100137585-A1 | FUSED HETEROARYL DERIVATIVES | PIK3CD, PIK3R3, PIK3C2A | MAPT 3923/4885RAB9A 613/4885NPC1 1963/4885 |
| US-20020151544-A1 | Fused heteroaryl derivatives | PIK3CD, PIK3R3, PIK3C2A | MAPT 3923/4885RAB9A 613/4885NPC1 1963/4885 |
| US-20050014771-A1 | Fused heteroaryl derivatives | PIK3CD, PIK3R3, PIK3C2A | MAPT 3923/4885RAB9A 613/4885NPC1 1963/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.